Serum cannabidiol, tetrahydrocannabinol (THC), and their native acid derivatives after transdermal application of a low-THC Cannabis sativa extract in beagles.

  title={Serum cannabidiol, tetrahydrocannabinol (THC), and their native acid derivatives after transdermal application of a low-THC Cannabis sativa extract in beagles.},
  author={Mary Beth Hannon and Kelly A. Deabold and Bryce N. Talsma and Alexander V. Lyubimov and Asif Iqbal and Alexander D Zakharov and Lauri-Jo Gamble and Joseph J. Wakshlag},
  journal={Journal of veterinary pharmacology and therapeutics},
Cannabinoids hold promise for treating health problems related to inflammation and chronic pain in dogs, in particular cannabidiol (CBD), and its native acid derivative cannabidiolic acid (CBDA). Information regarding systemic delivery of cannabinoids through transdermal routes is sparse. The purpose of this study was to determine pharmacokinetics of transdermal administration of a low-THC Cannabis sativa extract in healthy dogs. Six purpose-bred research beagles were treated with a transdermal… 
6 Citations

The Chemistry of Cannabis and Cannabinoids

  • P. Duggan
  • Biology
    Australian Journal of Chemistry
  • 2021
This Primer Review is designed to give a succinct overview of the chemistry of cannabis and cannabinoids and to provide a useful resource for chemistry undergraduates, postgraduates and their instructors, and experienced chemists who require a comprehensive and up to date summary of the field.

Current review of hemp-based medicines in dogs.

Clinical and pre-clinical studies and case reports were reviewed in this report to identify the main characteristics of hemp-based therapies in dogs, including its pharmacokinetics, pharmacodynamics, safety, and efficacy in the treatment of diseases.

Systematic Review on Transdermal/Topical Cannabidiol Trials: A Reconsidered Way Forward.

New clinical trials are urgently needed: they must demonstrate that outcomes are solely from CBD pharmacology, are reliable, unbiased, safe, and comparable, and rationally balance efficacy against potential harms and cost-effectiveness of CBD formulations.

Safety and Efficacy of the Therapeutic Use of Cannabis-Based Products in the Treatment of Dogs: An Integrative Review.

It is possible to infer safety in the administration of cannabis-based products for the treatment of dogs, especially products rich in cannabidiol (CBD), free or with low concentrations of tetrahydrocannabinol, under the conditions evaluated.



Heat exposure of Cannabis sativa extracts affects the pharmacokinetic and metabolic profile in healthy male subjects.

Results indicate that use of unheated extracts of C. SATIVA may lead to a beneficial change in metabolic pattern and possibly better tolerability.

Effect of cannabidiolic acid and ∆9-tetrahydrocannabinol on carrageenan-induced hyperalgesia and edema in a rodent model of inflammatory pain

CBDA or THC alone, as well as very low doses of combined CBDA and THC, has anti-inflammatory and anti-hyperalgesia effects in this animal model of acute inflammation.

Cannabidiolic Acid as a Selective Cyclooxygenase-2 Inhibitory Component in Cannabis

The lines of evidence in this study suggest that naturally occurring CBDA in cannabis is a selective inhibitor for COX-2.

A Report of Adverse Effects Associated With the Administration of Cannabidiol in Healthy Dogs

Cannabis-based therapies have been used for centuries for various medicinal purposes and CBD appeared to be well tolerated in dogs, but a more extensive safety study is necessary to determine if there are long-term effects of CBD on the liver and an association with diarrhea.

Cannabidiol bioavailability after nasal and transdermal application: effect of permeation enhancers

The results of this study indicated that CBD could be successfully delivered through the IN and transdermal routes, and the achievement of a significant steady-state plasma concentration indicates that CBD is useful for chronic pain treatment through this route of administration.

Pharmacokinetics and tolerability of oral cannabis preparations in patients with medication overuse headache (MOH)—a pilot study

Cannabis decoction and cannabis oil showed different pharmacokinetic properties, as well as distinct consequences on patients, and future studies should be performed to investigate the clinical efficacy in larger populations.

A Review of Human Studies Assessing Cannabidiol's (CBD) Therapeutic Actions and Potential

  • C. White
  • Medicine
    Journal of clinical pharmacology
  • 2019
Cannabidiol (CBD) is a highly touted product for many different disorders among the lay press, but in those diseases with evaluable human data, it generally has weak or very weak evidence.

Cannabidiol-transdermal delivery and anti-inflammatory effect in a murine model.

Cannabinoid Delivery Systems for Pain and Inflammation Treatment

This review explores the most recent developments, from preclinical to advanced clinical trials, in the cannabinoid delivery field, and focuses particularly on pain and inflammation treatment.